Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOR46 in Relapsed or Refractory Multiple Myeloma
NCT03650491Phase 1Completed
- Sponsor
- Fortis Therapeutics
- Start
- Apr 2019
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of FG-3246 in multiple myeloma (MM) (2 arms), sponsored by Fortis Therapeutics. Primary endpoints: Incidence of adverse events, Occurrence of dose-limiting toxicities and 1 more. Started Apr 2019; status: completed.
02
Drugs
FG-3246
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03650491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650491.